June 8, 2016
NGM Bio Initiates Phase 1 Clinical Trial of NGM313, a Proprietary Antibody with the Potential to Treat Type 2 Diabetes, Obesity and NASH
November 9, 2015
NGM Bio to Present Data Highlighting the Therapeutic Potential of NGM282 in Cholestatic Liver Diseases at AASLD’s The Liver Meeting® 2015
September 30, 2015
NGM Bio is named one of FierceBiotech’s “Fierce 15” Biotech Companies of 2015
There are no webcast at this time.
Media Inquiries: email@example.com